3.7(top 10%)
impact factor
2.3K(top 10%)
papers
123.0K(top 5%)
citations
150(top 2%)
h-index
3.8(top 10%)
impact factor
2.8K
all documents
129.4K
doc citations
226(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Dissecting components of reward: ‘liking’, ‘wanting’, and learningCurrent Opinion in Pharmacology20091,530
2Vitamin D: modulator of the immune systemCurrent Opinion in Pharmacology20101,025
3Antibacterial peptides for therapeutic use: obstacles and realistic outlookCurrent Opinion in Pharmacology2006901
4NMDA receptor subunits: function and pharmacologyCurrent Opinion in Pharmacology2007746
5Role of neurotrophic factors in depressionCurrent Opinion in Pharmacology2007610
6Novel trends in high-throughput screeningCurrent Opinion in Pharmacology2009550
7N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiencyCurrent Opinion in Pharmacology2007542
8The mechanisms of action of gabapentin and pregabalinCurrent Opinion in Pharmacology2006520
9Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunityCurrent Opinion in Pharmacology2009503
10Update on the antibiotic resistance crisisCurrent Opinion in Pharmacology2014501
11Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promisesCurrent Opinion in Pharmacology2008488
12PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology2015483
13Natural products in anticancer therapyCurrent Opinion in Pharmacology2001477
14Reward system and addiction: what dopamine does and doesn’t doCurrent Opinion in Pharmacology2007463
15Corticotropin-releasing factor receptors 1 and 2 in anxiety and depressionCurrent Opinion in Pharmacology2002459
16Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology2008444
17GABA-based therapeutic approaches: GABAA receptor subtype functionsCurrent Opinion in Pharmacology2006443
18Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacologyCurrent Opinion in Pharmacology2005438
19Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamineCurrent Opinion in Pharmacology2005428
20Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stressCurrent Opinion in Pharmacology2007418
21Renaissance in antibacterial discovery from actinomycetesCurrent Opinion in Pharmacology2008413
22Targeting mTOR signaling for cancer therapyCurrent Opinion in Pharmacology2003411
23Mechanism of action of memantineCurrent Opinion in Pharmacology2006390
24Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory responseCurrent Opinion in Pharmacology2006386
25The p38 MAP kinase pathway as a therapeutic target in inflammatory diseaseCurrent Opinion in Pharmacology2004382
26Neurobiology of craving, conditioned reward and relapseCurrent Opinion in Pharmacology2005374
27Targeting the androgen receptor pathway in prostate cancerCurrent Opinion in Pharmacology2008371
28Effects of nicotinic stimulation on cognitive performanceCurrent Opinion in Pharmacology2004357
29Parathyroid hormone: anabolic and catabolic actions on the skeletonCurrent Opinion in Pharmacology2015355
30Histone deacetylasesCurrent Opinion in Pharmacology2003354
31Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylationCurrent Opinion in Pharmacology2009350
32Inflammation and cancer: how friendly is the relationship for cancer patients?Current Opinion in Pharmacology2009343
33Angiotensin-converting enzyme 2 in lung diseasesCurrent Opinion in Pharmacology2006342
34Targeting death receptors in cancer with Apo2L/TRAILCurrent Opinion in Pharmacology2004336
35Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implicationsCurrent Opinion in Pharmacology2004326
36Natural products as a gold mine for arthritis treatmentCurrent Opinion in Pharmacology2007326
37Interplay between obesity and associated metabolic disorders: new insights into the gut microbiotaCurrent Opinion in Pharmacology2009325
38microRNAs and the immune responseCurrent Opinion in Pharmacology2009321
39Monoclonal antibody therapeutics: history and futureCurrent Opinion in Pharmacology2012320
40Ethanol and brain damageCurrent Opinion in Pharmacology2005307
41Glutamate systems in cocaine addictionCurrent Opinion in Pharmacology2004306
42ERK2: a logical AND gate critical for drug-induced plasticity?Current Opinion in Pharmacology2007304
43The role of serotonin receptors in the action of atypical antipsychotic drugsCurrent Opinion in Pharmacology2011304
44Gut microbiota, enteroendocrine functions and metabolismCurrent Opinion in Pharmacology2013300
45Oxidative stress and mitochondrial dysfunction in glaucomaCurrent Opinion in Pharmacology2013300
46Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide deliveryCurrent Opinion in Pharmacology2006294
47Stress hormones: physiological stress and regulation of metabolismCurrent Opinion in Pharmacology2009288
48PCP: from pharmacology to modelling schizophreniaCurrent Opinion in Pharmacology2005277
49Glutamate-based therapeutic approaches: clinical trials with NMDA antagonistsCurrent Opinion in Pharmacology2006277
50Targeting Hsp90: small-molecule inhibitors and their clinical developmentCurrent Opinion in Pharmacology2008277